Excaliard Begins Phase 2 Trials For EXC 001

Excaliard Pharmaceuticals (Excaliard) has initiated three proof of concept Phase 2 trials of EXC 001, an antisense medicine that reduces fibrosis, for the amelioration of skin scarring and other fibrotic disorders.

The US multicenter trials is expected to test the efficacy, safety, and tolerability of EXC 001 in two different models to evaluate the improvement of the appearance of scars in subjects undergoing elective abdominoplasty surgery and revision of scars associated with prior breast surgery.

Lincoln Krochmal, president and CEO of Excaliard, said: “The prevention and treatment of unsatisfactory skin scarring remains an important unmet medical need. We are delighted with our Phase 1 study results indicating EXC 001 delivered locally has a very impressive safety profile.

“We look forward to further evaluating the safety and efficacy of our novel therapeutic in Phase 2 trials for conditions in which the amelioration of scarring post-operatively would be highly desirable by the patient.”

Nicholas Dean, founder and chief scientific officer of Excaliard, said: “EXC 001 is an antisense medicine that inhibits fibrosis. In a variety of animal models of scar formation, EXC 001 has demonstrated positive and reproducible reductions in skin scar formation. EXC 001 is an exciting and novel approach to reducing skin scarring, and represents the first time an antisense medicine has been used for this significant, unmet medical need.”